Accretion Nutraveda IPO GMP, Date, Price & Details 2026

Accretion Nutraveda IPO GMP, Date, Price, Review, Financials & Complete Details (2026)

The SME IPO market has once again shifted into focus, and Accretion Nutraveda Limited has emerged as one of the most discussed upcoming offerings. With a strong growth trajectory, expanding manufacturing capabilities, and exposure to the rapidly growing nutraceutical and ayurvedic healthcare segment, the Accretion Nutraveda IPO has caught the attention of seasoned SME IPO investors.

Accretion Nutraveda Limited is based in Gujarat and operates as a Contract Development and Manufacturing Organization (CDMO). In simple terms, the company helps other brands develop, manufacture, and scale nutraceutical and ayurvedic products without building their own factories.

The Accretion Nutraveda Ltd IPO opens on January 28, 2026, and the company plans to raise funds to expand production capacity, invest in automation, and set up a new manufacturing facility. Given the recent performance of healthcare-related SME IPOs, investors are closely tracking the Accretion Nutraveda IPO GMP, valuation, and risk factors.

Accretion Nutraveda IPO: Key Details at a Glance

The IPO is a Book Built Issue and will be listed on the BSE SME platform.

Feature	Details
IPO Name	Accretion Nutraveda Limited IPO
IPO Open Date	Wednesday, January 28, 2026
IPO Close Date	Friday, January 30, 2026
Price Band	₹122 – ₹129 per equity share
Face Value	₹10 per share
Lot Size	1,000 shares
Minimum Application	2 Lots (2,000 shares)
Minimum Investment	₹2,58,000 (at upper price band)
Issue Size	Up to 19,20,000 equity shares
Issue Type	100% Fresh Issue
Listing Platform	BSE SME
Registrar	KFin Technologies Limited
Lead Manager	Sobhagya Capital Options Private Limited

Accretion Nutraveda IPO Timeline (Tentative)

Event	Date
IPO Opens	January 28, 2026
IPO Closes	January 30, 2026
Basis of Allotment	February 2, 2026 (Expected)
Refunds Initiated	February 3, 2026
Shares Credited	February 3, 2026
Listing Date	February 4, 2026 (Tentative)

Accretion Nutraveda IPO GMP (Grey Market Premium)

As of late January 2026, the Accretion Nutraveda IPO GMP is in the price discovery phase.

What does this mean for investors?

GMP is unofficial and speculative
It fluctuates based on:
- Subscription demand
- Overall SME IPO sentiment
- Liquidity conditions
- Market mood near listing

Key GMP Tracking Tips

Monitor GMP 2–3 days before listing
Combine GMP with subscription data
Avoid relying solely on GMP for investment decisions

Investors tracking Accretion Nutraveda Ltd IPO GMP should treat it as a sentiment indicator, not a guarantee of listing gains.

Business Overview: What Does Accretion Nutraveda Ltd Do?

Founded in 2021, Accretion Nutraveda Pvt Ltd operates in the healthcare manufacturing space as a CDMO. The company focuses on contract manufacturing rather than branding, which helps it scale faster with lower marketing expenses.

Product Portfolio

The company manufactures both ayurvedic and nutraceutical formulations, including:

Tablets
Capsules
Oral liquids
Powders
Ointments
Gels
Oils (external applications)

Therapeutic Segments Covered

Bone and joint care
Respiratory health
Women’s wellness
Digestive health
Liver care
Skin and hair care

Manufacturing Facility & Certifications

Accretion Nutraveda’s manufacturing unit is located in Sanand, Ahmedabad (Gujarat) and operates under strict quality guidelines.

Compliance & Certifications

GMP & WHO-GMP compliant
ISO 9001:2015
ISO 45001:2018
FSSC 22000
HALAL Certification

These certifications strengthen the company’s credibility as a reliable backend manufacturer for healthcare brands.

Financial Performance: Accretion Nutraveda Growth Story

The financial performance shows a sharp acceleration in FY25, with momentum continuing into FY26.

Financial Summary Table

Parameter	FY 2023	FY 2024	FY 2025	H1 FY 2026
Revenue (₹ Cr)	3.07	5.20	16.06	14.06
Net Profit (₹ Cr)	0.28	0.82	2.61	2.33
EBITDA (₹ Cr)	0.59	1.21	3.65	3.29
Total Borrowings (₹ Cr)	1.97	2.17	3.86	4.43
EPS (₹)	0.78	2.28	7.19	4.73*

*H1 FY26 EPS is non-annualized

Key Financial Observations

Revenue grew 3× from FY24 to FY25
H1 FY26 revenue already reached ~88% of FY25
Net profit margins improved significantly
Borrowings increased due to expansion plans
Operating cash flow remains negative (key concern)

Accretion Nutraveda IPO Valuation Analysis

At the upper price band of ₹129 per share:

Metric	Value
FY25 EPS	₹7.19
IPO P/E Ratio	~18×
Industry Positioning	Reasonable for SME CDMO
Risk Level	High

Valuation Takeaway

The valuation appears fair-to-slightly aggressive, justified by growth but sensitive to execution risks.

Objects of the Issue (Use of IPO Proceeds)

The company plans to deploy IPO proceeds for expansion and capacity building.

Fund Utilization Breakdown

Purpose	Amount
Automation	₹4.21 crore
New Manufacturing Facility	₹8.03 crore
Working Capital	₹5.50 crore
General Corporate Purposes	Balance

Accretion Nutraveda IPO Review: Key Risks Explained

1. Customer Concentration Risk

~88% revenue from top 10 clients
Loss of a major customer can impact earnings sharply

2. Geographic Concentration

Over 96% revenue from Gujarat
Regulatory or economic issues in one state pose risk

3. Legal & Compliance Risk

Criminal complaint by Assistant Drugs Controller
Related to failed quality standards for a tablet batch

4. Negative Operating Cash Flow

FY25: –₹2.21 crore
H1 FY26: –₹0.88 crore

5. Leased Assets

Manufacturing unit and head office are leased
Long-term stability risk

Who Should Consider the Accretion Nutraveda IPO?

Suitable For:

SME IPO investors
High-risk, high-growth portfolios
Investors bullish on nutraceutical CDMO theme

Not Suitable For:

Conservative investors
Income-focused investors
Short-term traders without SME experience

How to apply for the Accretion Nutraveda IPO?

You can apply through any stock trading app that supports BSE SME IPOs by selecting the Accretion Nutraveda IPO, choosing the required lot size, and approving the UPI mandate from your bank.

Final Verdict: Accretion Nutraveda IPO Review

The Accretion Nutraveda IPO presents a high-growth but high-risk opportunity. The company has delivered impressive revenue growth and is expanding capacity aggressively. However, investors must carefully evaluate the concentration risks, legal issues, and negative cash flow.

At ~18x earnings, the IPO is not cheap, but not excessively priced either. It suits investors who understand SME volatility and can tolerate risk.

FAQs

1. When does the Accretion Nutraveda IPO open?

January 28, 2026.

2. What is the Accretion Nutraveda IPO GMP today?

The GMP is currently in the discovery phase and fluctuates daily.

3. What is the price band of Accretion Nutraveda Ltd IPO?

₹122 to ₹129 per share.

4. What is the lot size?

1,000 shares per lot.

5. What is the minimum investment required?

₹2,58,000 for 2 lots.

6. Is Accretion Nutraveda Pvt Ltd profitable?

Yes, it reported ₹2.61 crore profit in FY25.

7. Why is operating cash flow negative?

Due to working capital requirements and expansion.

8. What does Accretion Nutraveda manufacture?

Nutraceutical and ayurvedic products including tablets, capsules, liquids, and topical formulations.

9. Where is the manufacturing facility located?

Sanand, Ahmedabad, Gujarat.

10. Is Accretion Nutraveda IPO risky?

Yes, due to customer concentration, legal issues, and SME nature.

11. What is the issue size?

Up to 19,20,000 equity shares.

12. Is the IPO a fresh issue?

Yes, 100% fresh issue.

13. Where will the shares be listed?

On the BSE SME platform.

14. Who is the registrar?

KFin Technologies Limited.

15. What is the main objective of the IPO?

Capacity expansion, automation, and working capital.

Disclaimer

This content is for educational purposes only and should not be considered investment advice. Please refer to the Red Herring Prospectus (RHP) of Accretion Nutraveda Limited before investing.